Ronatherapeutics
Shanghai, CN · 2 known investors
Rona Therapeutics develops siRNA-based therapeutics using its GAIA platform to target metabolic and cardiovascular conditions including hypertriglyceridemia, obesity, ASCVD, and MASH. Its pipeline includes APOC3, INHBE, PCSK9-Lp(a), and angiotensinogen-targeting candidates for patients with cardiovascular and metabolic diseases.
Founders & leadership
JH
Jinyu HuangChief Executive Officer, Founder
SS
Stella ShiinFounder & Chief Executive Officer, Chair of the Board
Investors · 2
Frequently asked questions
- What does Ronatherapeutics do?
- Rona Therapeutics develops siRNA-based therapeutics using its GAIA platform to target metabolic and cardiovascular conditions including hypertriglyceridemia, obesity, ASCVD, and MASH. Its pipeline includes APOC3, INHBE, PCSK9-Lp(a), and angiotensinogen-targeting candidates for patients with cardiovascular and metabolic diseases.
- Who founded Ronatherapeutics?
- Ronatherapeutics was founded by Jinyu Huang, Stella Shi.
- Who are Ronatherapeutics's investors?
- Ronatherapeutics's investors include LAV, Lilly Asia Ventures.
- Where is Ronatherapeutics headquartered?
- Ronatherapeutics is headquartered in Shanghai, CN.